Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

485
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
485
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

26
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
26
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

52
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
52
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

37
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
37
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

31
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
31
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

221
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
221

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TACTIC: A transfer learning framework to predict drug interactions in emerging pathogens.

Cell reports methods·2026
Same author

Plume Geometry Matters: Investigating the Contribution of Mass-Based Plume Geometry to Aerosol Delivery Efficiency in pMDIs.

AAPS PharmSciTech·2026
Same author

Mapping a Ternary Carbohydrate Design Space for Stable and Dispersible Protein Dry Powders.

Molecular pharmaceutics·2026
Same author

Strain-specific persistence of <i>Burkholderia cenocepacia</i> in the C3HeB/FeJ mouse model of pulmonary infection.

Journal of medical microbiology·2026
Same author

A Distribution-Based Metric for Quantifying Dispersibility in Dry Powder Inhalers.

Pharmaceutics·2026
Same author

Colistin-stabilized antisolvent precipitation enables engineering of microcrystalline niclosamide for inhalable composite powders.

International journal of pharmaceutics·2026

Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.1K

A Quality by Design Framework for Capsule-Based Dry Powder Inhalers.

Li Ding1, Ashlee D Brunaugh1, Sven Stegemann2

  • 1Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA.

Pharmaceutics
|August 28, 2021
PubMed
Summary

This review explores critical factors for capsule-based dry powder inhaler (cDPI) development using a Quality by Design (QbD) approach. Understanding powder-capsule-device interactions is key for reproducible lung drug delivery.

Keywords:
capsule activationcapsule fillingcapsule manufacturingcapsule storagedry powder inhalersinhalation capsulequality by design

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.9K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Related Experiment Videos

Last Updated: Oct 22, 2025

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.1K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.9K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Biotechnology

Background:

  • Capsule-based dry powder inhalers (cDPIs) are prevalent for pulmonary drug delivery.
  • Optimizing cDPIs requires understanding complex interactions between drug formulation, capsules, device, and patient.
  • A comprehensive analysis of capsule-specific factors in cDPIs is lacking.

Purpose of the Study:

  • To review critical factors for developing capsule-based dry powder inhalers (cDPIs).
  • To guide the application of a Quality by Design (QbD) approach in cDPI development.
  • To identify key considerations for manufacturing and control of cDPIs.

Main Methods:

  • Literature review focusing on capsule-based dry powder inhaler technology.
  • Analysis of Quality by Design (QbD) principles applied to cDPI development.
  • Identification of critical quality attributes (CQAs), material attributes (CMAs), and process parameters (CPPs).

Main Results:

  • Elucidating drug/formulation powder, capsule, and device interactions is crucial.
  • Defining the Quality Target Product Profile (QTPP) is essential for identifying CQAs.
  • Understanding CMAs and CPPs is vital for robust manufacturing and reproducible lung deposition.

Conclusions:

  • A QbD approach is recommended for cDPI development.
  • Systematic understanding of capsule-related factors enhances cDPI performance.
  • This review provides a framework for optimizing cDPIs through QbD principles.